API China: Novel HA offers drug delivery benefits

A NEW Bacillus-derived hyaluronic acid (HA) that is being highlighted at the API China in Suzhou, offers greater safety, better consistency, and improved performance, Novozymes Biopharma said.

In contrast to conventional methods, Novozymes Biopharma produces HA without the use of animal-derived raw materials and organic solvents. “Novozymes uses Bacillus subtilis rather than rooster combs or strains of Streptococcus bacteria to produce hyaluronic acid, and hence there is reduced toxicity and no animal residue,” explained Formulation manager Ole Moller Dall.

Preformulation time can be decreased since the shorter dissolving times and improved heat stability of Hyasis, Mr Dall also said

Improved half-life and bioavailability also means that the proprietary HA can deliver effective drug delivery and reduce dosing frequency, he added.

The 3-day API China (Autumn edition) ends November 15. The 2014 spring edition of API China, organised by Reed Sinopharm Exhibitions, will be held in Chengdu, China, from May 21-23.Air Huarache Classic